Risk Factors and elsewhere in this Form 10-K. All statements, other than statements of historical facts, included herein that address activities, events or developments that the Company expects or anticipates will or may occur in the future, are forward-looking statements, including statements regarding:  Advantages of the human tissues the Company distributes;  Plans, costs, and expected timeline regarding regulatory approval for PerClot, the distribution of PerClot in certain markets after the requisite regulatory approvals are obtained, and the Companys expectation that it will terminate its minimum purchase requirements after regulatory approval of PerClot;  Expectations regarding, and efforts to respond to the FDA questioning related to, the revised IDE filed for PerClot and the anticipated clinical trials to obtain PMA to distribute PerClot in the U.S.;  Potential benefits and additional applications of the Companys surgical adhesives, sealants, hemostats, and TMR treatment;  Anticipated timing of completion of the PEARL 8.0 post-approval study and full-market launch;  Revenue trend estimates for the Companys products and services for 2014;  Plans related to regulatory approval in certain markets for BioFoam, and the subsequent distribution of BioFoam in those markets;  The estimated European market opportunity for cardiovascular and parenchymal tissue sealing;  Commercialization plans for ProPatch;  The Companys beliefs regarding the adequacy of, and competitive advantages conferred by, its intellectual property protections;  The anticipated benefits of conducting a post-clearance study at the FDAs request to collect long-term clinical data for the CryoValve SGPV;  Plans regarding HeRO Graft product enhancements, estimates regarding the addressable worldwide market opportunity for the HeRO Graft, and the Companys intentions to introduce the HeRO Graft more broadly within Europe in 2014;  The Companys beliefs that the HeRO Graft will fit well within the Companys product portfolio and that a significant opportunity exists to introduce and expand the utilization of the HeRO Graft in the U.S.;  The Companys beliefs regarding the potential for competitive products and services to affect the market for the Companys products and services.  Expected benefits of the Companys marketing, educational and technical support efforts;  Anticipated benefits of providing on-site freezers;  Expected effect of discontinuance of tissue shipments into Europe beginning April 2014;  The Companys estimates and assessments of production levels and production capacity;  Expected use of the Companys additional laboratory space;  Anticipated payment of quarterly dividends each year;  The Companys expectations regarding the recoverability and realizability of deferred tax assets;  The Companys estimates of unreported loss liabilities, including unreported product and tissue processing liability claims, the assumptions used to establish those estimates, and the Companys belief that those assumptions provide a reasonable basis for the estimates; 34  The Companys estimates of fair value of acquired assets, and its belief that the estimates are reasonable;  The expectation that the Company will continue to renew certain acquired contracts and procurement agreements for the foreseeable future;  Expectations regarding the recognition of stock compensation expense;  The Companys assessment of the effect of adopting new accounting standards regarding the testing of certain intangible assets for impairment and the reporting of certain reclassified amounts;  Plans and expectations regarding research and development of new technologies and products;  The Companys expectations about whether and when it may receive additional payments related to its sale of Medafor stock;  The Companys expectation that general, administrative, and marketing expenses will increase in 2014 as compared to 2013, before consideration of the effects of litigation and business development expenses;  Managements beliefs that the potential patent infringement litigation between CryoLife and Medafor or Bard could occur as early as 2014, and managements belief that if litigation occurs the cost of this litigation would be material;  Expectations that research and development spending will increase materially in 2014;  Expectations regarding business consolidations in the healthcare industry that could exert downward pressure on fees charged by the Company;  The Companys beliefs regarding sales of BioGlue, PerClot, handpieces, and laser consoles and the factors affecting such sales;  The Companys belief that healthcare policy and law changes may have a material adverse effect on the business;  The Companys belief that the underlying collateral is sufficient to secure the Companys $2.0 million loan to ValveXchange;  The Companys belief that any issues related to the FDAs observations in the CryoLife Form 483 and the Warning Letter will not have a material effect on the Company;  The Companys belief that any issues related to the FDAs observations in the Hemosphere Form 483 will not have a material effect on the Company;  The Companys beliefs regarding the seasonal nature of the demand for some of its products and services;  The adequacy of the Companys financial resources and its belief that it will have sufficient cash to meet its operational liquidity needs for at least the next twelve months;  Estimates of contingent payments and royalties that may be paid by the Company and the timing of such payments;  The possibility of a patent infringement lawsuit with Medafor, the impact of such a lawsuit, and the Companys belief that PerClot will not infringe Medafors patent;  The impact on cash flows of funding business development activities and the potential need to obtain additional borrowing capacity or financing;  The Companys expectations regarding the source of any future payments related to any unreported product or tissue processing liability claims;  Anticipated impact of changes in prevailing economic conditions, interest rates, and foreign currency exchange rates;  The constraints imposed on the Company by its lender under the existing credit facility;  Plans regarding acquisition and investment opportunities of complementary product lines and companies;  The Companys beliefs regarding the state of relations with its employees;  Plans regarding the licensing of the Companys technology to third parties for non-competing uses;  Anticipated effect of suppliers/sources inability to deliver critical raw materials or tissues and/or the Company having to source supply from an alternate supplier;  Issues that may affect the Companys future financial performance and cash flows; and  Other statements regarding future plans and strategies, anticipated events, or trends. 35 These statements are based on certain assumptions and analyses made by the Company in light of its experience and its perception of historical trends, current conditions, and expected future developments as well as other factors it believes are appropriate in the circumstances. However, whether actual results and developments will conform with the Companys expectations and predictions is subject to a number of risks and uncertainties which could cause actual results to differ materially from the Companys expectations, including, without limitation, in addition to those specified in the text surrounding such statements, the risk factors discussed in Item 1A of this Form 10-K and other factors, many of which are beyond the control of CryoLife. Consequently, all of the forward-looking statements made in this Form 10-K are qualified by these cautionary statements, and there can be no assurance that the actual results or developments anticipated by the Company will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Company or its business or operations. The Company assumes no obligation to update publicly any such forward-looking statements, whether as a result of new information, future events, or otherwise. 36 Item 1B. Unresolved Staff Comments. The Company has no unresolved written comments received from the staff of the SEC regarding its periodic or current reports under the Securities Exchange Act of 1934 not less than 180 days before December 31, 2013 (the end of the fiscal year to which this Form 10-K relates). 